Progressive multifocal leukoencephalopathy (PML): clinical features
Evidence-based neurology checklist on progressive multifocal leukoencephalopathy (pml): clinical features: Epidemiological features PML develops after a mean interval of about 2 years after Natalizumab treatment This risk is lower with low natalizumab trough concentrations It evolves over weeks…
Epidemiological features
- PML develops after a mean interval of about 2 years after Natalizumab treatment
- This risk is lower with low natalizumab trough concentrations
- It evolves over weeks
- The mortality is 29%
- The one-year survival is 38-62%
Neurological features
Poor prognostic features
Factors that do not affect prognosis
Causes of death
References
- Hunt D, Giovannoni G. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol 2012; 12:25-35.
- Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9:438-446.
- Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011; 76:1697-1704.
- Warnke C, Menge T, Hartung H-P, et al. Natalizumab and progressive multifocal leukoencephalopathy. Arch Neurol 2010; 67:923-930.
- Glissen LMY, Toorop AA, Schipper PM, et al. Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2025 (Online ahead of print).
